Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population

Abstract

This study was funded by Allergan. The authors received no compensation related to the development of the manuscript. Buono and Andrae are employees of Allergan. Mathur is an employee of Axtria. Averitt was an employee of Axtria at the time this study was conducted. Data from this manuscript have previously been presented in poster format by Buono at the American College of Gastroenterology Annual Scientific Meeting; Honolulu, Hawaii; October 16-21, 2015. Mathur and Averitt were involved in conducting the study analyses. All authors were involved in the study design, interpretation of the data, and preparation of the manuscript. The authors take full responsibility for the scope, direction, and content of the manuscript and have approved the submitted manuscript.

Irritable bowel syndrome, mental health, and quality of life: Data from a population‐based survey in Germany (SHIP‐Trend‐0)

“…Interestingly, we found not only IBS‐related increased demand for healthcare in primary care settings—which could possibly be related to symptom persistence or psychological factors—but also in inpatient treatments. Similar findings have already been published, but are difficult to explain—especially when considering the benign nature of IBS. A possible reason may be the patients' wish for intensive and partly repeated diagnostic procedures, which is common in patients with somatic symptom disorders.…”

Targeting the gut microbiota for the treatment of irritable bowel syndrome

“…IBS is a common gastrointestinal (GI) disorder with an estimated global prevalence of around 10% . Its high prevalence and chronic nature decrease patients' quality of life (QoL) and place a significant economic burden on healthcare systems in both western and eastern countries …”

Review article: an analysis of safety profiles of treatments for diarrhoea‐predominant irritable bowel syndrome

“…IBS is further categorised by its predominant bowel habit, including diarrhoea‐predominant IBS (IBS‐D; >25% Bristol Stool Scale form types 6 or 7 and <25% Bristol Stool Scale form types 1 or 2), constipation‐predominant IBS (>25% Bristol Stool Scale form types 1 or 2 and <25% Bristol Stool Scale form types 6 or 7), or mixed form IBS (>25% Bristol Stool Scale form types 1 or 2 and >25% Bristol Stool Scale form types 6 or 7) . IBS, including IBS‐D, is associated with reduced quality of life and increased healthcare costs …”

“…In the United States, IBS is usually managed on an outpatient basis . For patients with IBS‐D included in a US commercially insured population (2013), mean all‐cause annual healthcare costs (eg, diagnostic tests and laboratory or radiology services [50.3%], prescriptions [19.5%], inpatient admissions [13.6%], emergency department visits [8.5%], and outpatient office visits [8.1%]) were estimated at $13 038, an amount $8768 in excess of that of individuals without IBS‐D ( P < 0.001) …”